Unknown

Dataset Information

0

Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer.


ABSTRACT:

Objective

To assess the efficacy and toxicity of cediranib, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, in patients with metastatic castration-resistant prostate cancer (CRPC) previously treated with docetaxel-based therapy.

Patients and methods

The study used a Simon two-stage trial design, which required at least two of 12 patients in the first cohort to be progression-free at 6 months. We enrolled a total of 35 evaluable patients who all received cediranib 20 mg orally daily. In a second cohort, 23 additional patients received prednisone 10 mg daily with cediranib. Endpoints included tumour response, progression-free survival (PFS), overall survival (OS), vascular permeability via dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI), and toxicity.

Results

A total of 59 patients were enrolled, of whom 67% had received two or more previous chemotherapy regimens. Six of 39 patients with measurable disease had confirmed partial responses and one had an unconfirmed partial response. At 6 months, 43.9% of patients were progression-free; the median PFS and OS periods for all patients were 3.7 months and 10.1 months, respectively. We found that the DCE-MRI variables baseline transport constant (Ktrans ) and rate constant at day 28 were significantly associated with PFS in univariate analyses, but only baseline Ktrans remained significant when considered jointly. The most frequent toxicities were hypertension, fatigue, anorexia and weight loss; the addition of prednisone reduced the incidence of constitutional toxicities.

Conclusion

This study demonstrated that cediranib was generally well tolerated with some anti-tumour activity in highly pretreated patients with metastatic CRPC who had progressive disease after docetaxel-based therapy.

SUBMITTER: Dahut WL 

PROVIDER: S-EPMC3660464 | biostudies-literature | 2013 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications


<h4>Objective</h4>To assess the efficacy and toxicity of cediranib, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, in patients with metastatic castration-resistant prostate cancer (CRPC) previously treated with docetaxel-based therapy.<h4>Patients and methods</h4>The study used a Simon two-stage trial design, which required at least two of 12 patients in the first cohort to be progression-free at 6 months. We enrolled a total of 35 evaluable patients w  ...[more]

Similar Datasets

| S-EPMC4281773 | biostudies-literature
| S-EPMC3394097 | biostudies-literature
| S-EPMC6387685 | biostudies-literature
| S-EPMC2860408 | biostudies-literature
| S-EPMC8571235 | biostudies-literature
| S-EPMC10762051 | biostudies-literature
| S-EPMC4627245 | biostudies-literature
| S-EPMC6902637 | biostudies-literature
| S-EPMC4257751 | biostudies-literature
| S-EPMC5315609 | biostudies-literature